Shares of HilleVax, Inc. (NASDAQ:HLVX – Get Free Report) were down 1.5% on Friday after the company announced weaker than expected quarterly earnings. The stock traded as low as $1.85 and last traded at $1.91. Approximately 150,420 shares changed hands during mid-day trading, a decline of 66% from the average daily volume of 440,025 shares. The stock had previously closed at $1.94.
The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.10).
Wall Street Analyst Weigh In
Separately, HC Wainwright reiterated a “neutral” rating and issued a $2.00 price target on shares of HilleVax in a research report on Monday, August 12th. Six equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, HilleVax has a consensus rating of “Hold” and an average price target of $9.20.
Hedge Funds Weigh In On HilleVax
Several hedge funds and other institutional investors have recently added to or reduced their stakes in HLVX. EntryPoint Capital LLC bought a new stake in HilleVax during the first quarter worth about $80,000. Tidal Investments LLC bought a new stake in HilleVax during the first quarter worth about $207,000. Maven Securities LTD bought a new stake in HilleVax during the second quarter worth about $217,000. BML Capital Management LLC bought a new stake in HilleVax during the third quarter worth about $35,000. Finally, Algert Global LLC bought a new stake in HilleVax during the second quarter worth about $519,000. 86.42% of the stock is currently owned by hedge funds and other institutional investors.
HilleVax Price Performance
The company has a 50 day simple moving average of $1.81 and a 200-day simple moving average of $6.20. The stock has a market cap of $95.08 million, a P/E ratio of -0.56 and a beta of 0.78.
HilleVax Company Profile
HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.
See Also
- Five stocks we like better than HilleVax
- What Are Growth Stocks and Investing in Them
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
- Russell 2000 Index, How Investors Use it For Profitable Trading
- MarketBeat Week in Review – 11/4 – 11/8
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Trump’s Return: Which Sectors Will Benefit Most?
Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with MarketBeat.com's FREE daily email newsletter.
